89bio Announces Additional Data from the ENLIVEN Phase 2b :

—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated...

Related Keywords

San Francisco , California , United States , Massachusetts , Boston , Sheryl Seapy , Hank Mansbach , Annie Chang , Lifesci Advisors , Nasdaq , Drug Administration , Linkedin , Exchange Commission , Liver Meeting , Chief Medical Officer , Non Invasive Tests , Breakthrough Therapy , New England Journal , Breakthrough Therapy Designation , Annual Report , Safe Harbor , Private Securities Litigation Reform Act , Sci Advisors , Nasdaq Etnb , 89bio , Nc ,